肝内胆管癌IDH1突变瘤内呈空间同质性
该回顾性研究纳入35例肝内胆管癌患者共117份空间不同区域的FFPE样本,用NGS确定基线IDH1状态并用Idylla™检测所有肿瘤区域,不一致者以dPCR验证。结果发现不一致仅由技术或检测误差导致,非真实生物学异质性,所有IDH1突变肿瘤各区域状态一致,提示单样本检测足以可靠判定IDH1状态。
要点
- 肝内胆管癌IDH1突变在空间上呈同质性,支持其为早期克隆事件。
- 单样本分子检测即可可靠确定IDH1状态,用于靶向治疗患者筛选。
- Idylla™与NGS结果不一致时需用dPCR验证以排除技术误差。
核心结论
- 肝内胆管癌IDH1突变在空间上呈同质性,支持其作为早期克隆事件。
- 单样本分子检测足以可靠确定IDH1状态并筛选IDH1靶向治疗患者。
研究设计与样本
- 回顾性分析35例组织学确诊的肝内胆管癌患者,共117份空间不同区域的FFPE肿瘤样本。
- 基线IDH1状态由常规NGS确定,所有肿瘤区域随后用Idylla™ IDH1-2突变检测,不一致者用dPCR验证。
主要发现
- 基线NGS在22.8%(8/35)的患者中检出IDH1突变。
- Idylla™检测在5/117份样本(4.2%)中显示与基线不一致的结果。
- dPCR验证表明这些不一致源于技术限制或检测相关误差,而非真实生物学异质性。
- 验证后所有IDH1突变肿瘤在各分析区域均显示一致的突变状态。
临床怎么用
- 对肝内胆管癌患者,单样本分子检测即可可靠判定IDH1状态,无需多区域取样。
- IDH1检测结果可用于筛选适合IDH1靶向治疗的患者。
- 当不同检测方法结果不一致时,应通过dPCR等验证排除技术误差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: IDH1 mutations occur in approximately 10%-20% of intrahepatic cholangiocarcinoma (iCCA) and constitute an established target for molecularly guided therapy. As routine molecular diagnostics are commonly based on a single tumour sample, intratumoral heterogeneity could affect the reliable detection of actionable mutations. This study assessed the spatial heterogeneity of IDH1 mutations in iCCA. METHODS: Patients with histologically confirmed iCCA who underwent routine next-generation sequencing (NGS) and had multiple available formalin-fixed paraffin-embedded (FFPE) tumour samples were retrospectively analysed. Baseline IDH1 status was determined by NGS. All available tumour regions were subsequently tested using the Idylla™ IDH1-2 Mutation Assay. Blocks where the Idylla™ IDH1 mutational status was discordant with baseline status were validated by digital polymerase chain reaction (dPCR). RESULTS: Thirty-five patients with iCCA were included, yielding 117 FFPE samples from spatially distinct tumour regions. Baseline NGS identified IDH1 mutations in 22.8% (8/35) of patients. Idylla™ testing revealed discordant results in 5 of 117 samples (4.2%). Validation by dPCR demonstrated that these discordances were attributable to technical limitations or assay-related errors rather than true biological heterogeneity. Following validation, all IDH1-mutated tumours showed concordant mutation status across all analysed tumour regions. CONCLUSIONS: IDH1 mutations appear to be spatially homogeneous in iCCA, supporting their role as an early clonal event. These findings indicate that single-sample molecular testing is sufficient for reliable determination of IDH1 status and patient selection for IDH1-targeted therapies.
引用
- Weidmann S, Ebner S, Srivastava A, et al. Intratumoral IDH1 mutation status in intrahepatic cholangiocarcinoma is homogeneous. Histopathology. 2026. PMID: 42596722. doi:10.1111/his.70266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。